BioCanRx, and partners, announce funding to manufacture first made-in-Canada CAR-T cells
Development of promising engineered T cell therapy part of $11 million investment in 16 collaborative research projects in novel therapies to cure cancer OTTAWA, ON – Wednesday, February 15, 2017, 10 a.m. ET - BioCanRx, and its partners, today...
Read More